CDK6 and plasma cell myeloma: Given that CDK6 upregulation was found in lenalidomide-resistant patients and induced expression reduced lenalidomide-sensitivity, we next tested the effects of the CDK6 inhibitor palbociclib36,37 in multiple myeloma cell lines.